{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:20:55Z","timestamp":1783635655330,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11095-026-04091-7","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T18:22:16Z","timestamp":1778005336000},"page":"2041-2053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PK-PD Modeling Suggests Tumor Heterogeneity Limits Preclinical to Clinical Translation of Enzalutamide in Prostate Cancer"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-5337","authenticated-orcid":false,"given":"Se Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3818-2252","authenticated-orcid":false,"given":"Robert","family":"Bies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-0440","authenticated-orcid":false,"given":"Donald E.","family":"Mager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"3","key":"4091_CR1","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1124\/jpet.112.191957","volume":"341","author":"CC Wong","year":"2012","unstructured":"Wong CC, Cheng KW, Rigas B. Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther. 2012;341(3):572\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"4091_CR2","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9929.1000356","author":"M Dhandapani","year":"2017","unstructured":"Dhandapani M, Goldman A. Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools. J Mol Biomark Diagn. 2017. https:\/\/doi.org\/10.4172\/2155-9929.1000356.","journal-title":"J Mol Biomark Diagn"},{"key":"4091_CR3","doi-asserted-by":"publisher","first-page":"1164535","DOI":"10.3389\/fonc.2023.1164535","volume":"13","author":"M Proietto","year":"2023","unstructured":"Proietto M, Crippa M, Damiani C, Pasquale V, Sacco E, Vanoni M, et al. Tumor heterogeneity: preclinical models, emerging technologies, and future applications. Front Oncol. 2023;13:1164535.","journal-title":"Front Oncol"},{"issue":"4","key":"4091_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.trecan.2018.02.003","volume":"4","author":"HM Levitin","year":"2018","unstructured":"Levitin HM, Yuan J, Sims PA. Single-cell transcriptomic analysis of tumor heterogeneity. Trends Cancer. 2018;4(4):264\u20138.","journal-title":"Trends Cancer"},{"issue":"6","key":"4091_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/clpt.2008.52","volume":"83","author":"DE Mager","year":"2008","unstructured":"Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008;83(6):909\u201312.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"4091_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","volume":"18","author":"MC Haffner","year":"2021","unstructured":"Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18(2):79\u201392.","journal-title":"Nat Rev Urol"},{"issue":"5928","key":"4091_CR7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787\u201390.","journal-title":"Science"},{"issue":"10","key":"4091_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40262-015-0271-5","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt JS, Beddo V, et al. Clinical pharmacokinetic studies of enzalutamide. Clin Pharmacokinet. 2015;54(10):1043\u201355.","journal-title":"Clin Pharmacokinet"},{"key":"4091_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1085\/jgp.21.1.107","volume":"21","author":"T Teorell","year":"1937","unstructured":"Teorell T. Studies on the diffusion effect upon ionic distribution: II. experiments on ionic accumulation. J Gen Physiol. 1937;21:107\u201322.","journal-title":"J Gen Physiol"},{"issue":"8","key":"4091_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.41","volume":"2","author":"H Jones","year":"2013","unstructured":"Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol. 2013;2(8):e63.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"4091_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/clpt.2012.65","volume":"92","author":"A Rostami-Hodjegan","year":"2012","unstructured":"Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92(1):50\u201361.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"4091_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s13318-016-0374-x","volume":"42","author":"Y Ohtsu","year":"2017","unstructured":"Ohtsu Y, Gibbons JA, Suzuki K, Fitzsimmons ME, Nozawa K, Arai H. Absorption, distribution, metabolism, and excretion of the androgen receptor inhibitor Enzalutamide in rats and dogs. Eur J Drug Metab Pharmacokinet. 2017;42(4):611\u201326.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"4091_CR13","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1007\/s12272-015-0592-9","volume":"38","author":"TH Kim","year":"2015","unstructured":"Kim TH, Jeong JW, Song JH, Lee KR, Ahn S, Ahn SH, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015;38(11):2076\u201382.","journal-title":"Arch Pharm Res"},{"key":"4091_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jpba.2018.04.038","volume":"156","author":"SP Sulochana","year":"2018","unstructured":"Sulochana SP, Saini NK, Daram P, Polina SB, Mullangi R. Validation of an LC-MS\/MS method for simultaneous quantitation of enzalutamide, N-desmethylenzalutamide, apalutamide, darolutamide and ORM-15341 in mice plasma and its application to a mice pharmacokinetic study. J Pharm Biomed Anal. 2018;156:170\u201380.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"4091_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5599\/admet.557","volume":"6","author":"NKSPS Saini","year":"2018","unstructured":"Saini NKSPS, Zainuddin M, Mullangi R. Development and validation of a novel method for simultaneous quantification of enzalutamide, darolutamide and their active metabolites in mice dried blood spots using LC-MS\/MS: Application to pharmacokinetic study in mice. ADMET. 2018;6(3):242\u201357.","journal-title":"ADMET"},{"issue":"3","key":"4091_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10637-018-0676-8","volume":"37","author":"A Mahipal","year":"2019","unstructured":"Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, et al. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs. 2019;37(3):473\u201381.","journal-title":"Invest New Drugs"},{"key":"4091_CR17","unstructured":"Center for drug evaluation and research application number: 203415Orig1s000. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203415Orig1s000PharmR.pdf.\u00a0 Accessed 12 Nov 2024"},{"issue":"5","key":"4091_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333.","journal-title":"N Engl J Med"},{"issue":"3","key":"4091_CR19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/0008-5472.CAN-03-2524","volume":"64","author":"M Simeoni","year":"2004","unstructured":"Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004;64(3):1094\u2013101.","journal-title":"Cancer Res"},{"issue":"2","key":"4091_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10928-014-9352-6","volume":"41","author":"JM Harrold","year":"2014","unstructured":"Harrold JM, Abraham AK. Ubiquity: a framework for physiological\/mechanism-based pharmacokinetic\/pharmacodynamic model development and deployment. J Pharmacokinet Pharmacodyn. 2014;41(2):141\u201351.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"4091_CR21","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0302-5","volume":"21","author":"K Kay","year":"2019","unstructured":"Kay K, Dolcy K, Bies R, Shah DK. Estimation of solid tumor doubling times from progression-free survival plots using a novel statistical approach. AAPS J. 2019;21(2):27.","journal-title":"AAPS J"},{"issue":"3","key":"4091_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10928-010-9156-2","volume":"37","author":"NL Jumbe","year":"2010","unstructured":"Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn. 2010;37(3):221\u201342.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"4091_CR23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/bcp.13891","volume":"85","author":"N Snelder","year":"2019","unstructured":"Snelder N, Drenth HJ, Riber Bergmann K, Wood ND, Hibberd M, Scott G. Population pharmacokinetic-pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin. Br J Clin Pharmacol. 2019;85(6):1247\u201359.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"4091_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"12","key":"4091_CR25","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1002\/psp4.13225","volume":"13","author":"Y Otani","year":"2024","unstructured":"Otani Y, Zhao Y, Wang G, Labotka R, Rogge M, Gupta N, et al. Modeling serum M-protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone. CPT Pharmacometrics Syst Pharmacol. 2024;13(12):2124\u201336.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"4091_CR26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/psp4.13128","volume":"13","author":"M Cerou","year":"2024","unstructured":"Cerou M, Thai HT, Deyme L, Fliscounakis-Huynh S, Comets E, Cohen P, et al. Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: leveraging data from amcenestrant early phase I-II trials. CPT Pharmacometrics Syst Pharmacol. 2024;13(6):941\u201353.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"4091_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF01062336","volume":"10","author":"H Boxenbaum","year":"1982","unstructured":"Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm. 1982;10(2):201\u201327.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"6","key":"4091_CR28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1476-5381.2009.00267.x","volume":"157","author":"V Sharma","year":"2009","unstructured":"Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol. 2009;157(6):907\u201321.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"4091_CR29","first-page":"428","volume":"10","author":"W Xiong","year":"2021","unstructured":"Xiong W, Friese-Hamim M, Johne A, Stroh C, Klevesath M, Falchook GS, et al. Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. CPT: Pharmacometrics & Systems Pharmacology. 2021;10(5):428\u201340.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"18","key":"4091_CR30","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1158\/1078-0432.CCR-13-0260","volume":"19","author":"H Xiang","year":"2013","unstructured":"Xiang H, Bender BC, Reyes AE, Merchant M, Jumbe NL, Romero M, et al. Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development. Clin Cancer Res. 2013;19(18):5068\u201378.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4091_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1208\/s12248-019-0332-z","volume":"21","author":"A Betts","year":"2019","unstructured":"Betts A, Haddish-Berhane N, Shah DK, van der Graaf PH, Barletta F, King L, et al. A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART((R)). AAPS J. 2019;21(4):66.","journal-title":"AAPS J"},{"issue":"2","key":"4091_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10928-018-9577-x","volume":"45","author":"DK Shah","year":"2018","unstructured":"Shah DK, Loganzo F, Haddish-Berhane N, Musto S, Wald HS, Barletta F, et al. Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK\/PD modeling approach. J Pharmacokinet Pharmacodyn. 2018;45(2):339\u201349.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"4091_CR33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10928-020-09702-3","volume":"47","author":"A Betts","year":"2020","unstructured":"Betts A, Clark T, Jasper P, Tolsma J, van der Graaf PH, Graziani EI, et al. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. J Pharmacokinet Pharmacodyn. 2020;47(5):513\u201326.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"4091_CR34","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1208\/s12248-016-9991-1","volume":"19","author":"T Cardilin","year":"2017","unstructured":"Cardilin T, Almquist J, Jirstrand M, Sostelly A, Amendt C, El Bawab S, et al. Tumor Static Concentration Curves in Combination Therapy. AAPS J. 2017;19(2):456\u201367.","journal-title":"AAPS J"},{"issue":"4","key":"4091_CR35","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1208\/s12248-017-0071-y","volume":"19","author":"AP Singh","year":"2017","unstructured":"Singh AP, Shah DK. Application of a PK-PD modeling and simulation-based strategy for clinical translation of antibody-drug conjugates: a case study with trastuzumab emtansine (T-DM1). AAPS J. 2017;19(4):1054\u201370.","journal-title":"AAPS J"},{"issue":"6","key":"4091_CR36","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10928-012-9276-y","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK\/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012;39(6):643\u201359.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"4091_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10928-025-09970-x","volume":"52","author":"D Ronchi","year":"2025","unstructured":"Ronchi D, Tosca EM, Magni P. Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach. J Pharmacokinet Pharmacodyn. 2025;52(3):24.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"4091_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00272-w","volume":"6","author":"R Ge","year":"2022","unstructured":"Ge R, Wang Z, Cheng L. Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance. NPJ Precis Oncol. 2022;6(1):31.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"4091_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8(1):160.","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"4091_CR40","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1158\/0008-5472.CAN-15-0727","volume":"75","author":"JW Cassidy","year":"2015","unstructured":"Cassidy JW, Caldas C, Bruna A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res. 2015;75(15):2963\u20138.","journal-title":"Cancer Res"},{"issue":"6","key":"4091_CR41","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.molonc.2014.06.005","volume":"8","author":"RA Burrell","year":"2014","unstructured":"Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8(6):1095\u2013111.","journal-title":"Mol Oncol"},{"issue":"5","key":"4091_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10928-023-09867-7","volume":"50","author":"Y Otsuka","year":"2023","unstructured":"Otsuka Y, Poondru S, Bonate PL, Rose RH, Jamei M, Ushigome F, et al. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates. J Pharmacokinet Pharmacodyn. 2023;50(5):365\u201376.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"4091_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2174\/1872312810666160729124745","volume":"10","author":"R Narayanan","year":"2016","unstructured":"Narayanan R, Hoffmann M, Kumar G, Surapaneni S. Application of a \u201cfit for purpose\u201d PBPK model to investigate the CYP3A4 induction potential of enzalutamide. Drug Metab Lett. 2016;10(3):172\u20139.","journal-title":"Drug Metab Lett"},{"key":"4091_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27196666","author":"CY Chang","year":"2022","unstructured":"Chang CY, Chen JT, Chen TH, Chen RM. Enzalutamide induces apoptotic insults to human drug-resistant and -sensitive glioblastoma cells via an intrinsic Bax-mitochondrion-cytochrome C caspase cascade activation pathway. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27196666.","journal-title":"Molecules"},{"issue":"9","key":"4091_CR45","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","volume":"36","author":"TA Traina","year":"2018","unstructured":"Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O\u2019Shaughnessy J, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36(9):884\u201390.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4091_CR46","doi-asserted-by":"publisher","first-page":"e1825","DOI":"10.1634\/theoncologist.2020-0521","volume":"25","author":"JJ Harding","year":"2020","unstructured":"Harding JJ, Kelley RK, Tan B, Capanu M, Do GK, Shia J, et al. Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist. 2020;25(12):e1825\u201336.","journal-title":"Oncologist"},{"issue":"1","key":"4091_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2021.10.087","volume":"164","author":"BL Manning-Geist","year":"2022","unstructured":"Manning-Geist BL, Gordhandas SB, Giri DD, Iasonos A, Zhou Q, Girshman J, et al. Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. Gynecol Oncol. 2022;164(1):12\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4091_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-025-07128-z","volume":"18","author":"T Kawahara","year":"2025","unstructured":"Kawahara T, Kandori S, Kojima T, Mathis BJ, Shiga M, Nishiyama H. Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study. BMC Res Notes. 2025;18(1):47.","journal-title":"BMC Res Notes"},{"key":"4091_CR49","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2014.0233","author":"J Lawrence","year":"2015","unstructured":"Lawrence J, Cameron D, Argyle D. Species differences in tumour responses to cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci. 2015. https:\/\/doi.org\/10.1098\/rstb.2014.0233.","journal-title":"Philos Trans R Soc Lond B Biol Sci"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04091-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04091-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04091-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:01:19Z","timestamp":1783634479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04091-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4091"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04091-7","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}